321 related articles for article (PubMed ID: 36562884)
61. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
Vingtdeux V; Davies P; Dickson DW; Marambaud P
Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
[TBL] [Abstract][Full Text] [Related]
62. Pharmacological approaches of neurofibrillary degeneration.
Iqbal K; Grundke-Iqbal I
Curr Alzheimer Res; 2005 Jul; 2(3):335-41. PubMed ID: 15974899
[TBL] [Abstract][Full Text] [Related]
63. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.
Iqbal K; Gong CX; Liu F
Expert Opin Ther Targets; 2014 Mar; 18(3):307-18. PubMed ID: 24387228
[TBL] [Abstract][Full Text] [Related]
64. Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?
Alavi Naini SM; Soussi-Yanicostas N
Oxid Med Cell Longev; 2015; 2015():151979. PubMed ID: 26576216
[TBL] [Abstract][Full Text] [Related]
65. Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.
Chanu SI; Sarkar S
Mol Neurobiol; 2017 May; 54(4):2706-2719. PubMed ID: 27000837
[TBL] [Abstract][Full Text] [Related]
66. Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury?
Collins-Praino LE; Corrigan F
Brain Behav Immun; 2017 Feb; 60():369-382. PubMed ID: 27686843
[TBL] [Abstract][Full Text] [Related]
67. Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration.
De Jesús-Cortés HJ; Nogueras-Ortiz CJ; Gearing M; Arnold SE; Vega IE
Neuroreport; 2012 Nov; 23(16):942-6. PubMed ID: 22975846
[TBL] [Abstract][Full Text] [Related]
68. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
[TBL] [Abstract][Full Text] [Related]
69. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
70. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
71. Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation.
Stefanoska K; Gajwani M; Tan ARP; Ahel HI; Asih PR; Volkerling A; Poljak A; Ittner A
Sci Adv; 2022 Jul; 8(27):eabl8809. PubMed ID: 35857446
[TBL] [Abstract][Full Text] [Related]
72. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
Brunden KR; Ballatore C; Lee VM; Smith AB; Trojanowski JQ
Biochem Soc Trans; 2012 Aug; 40(4):661-6. PubMed ID: 22817712
[TBL] [Abstract][Full Text] [Related]
73. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia.
Planel E; Bretteville A; Liu L; Virag L; Du AL; Yu WH; Dickson DW; Whittington RA; Duff KE
FASEB J; 2009 Aug; 23(8):2595-604. PubMed ID: 19279139
[TBL] [Abstract][Full Text] [Related]
74. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
[TBL] [Abstract][Full Text] [Related]
75. d-Pinitol promotes tau dephosphorylation through a cyclin-dependent kinase 5 regulation mechanism: A new potential approach for tauopathies?
Medina-Vera D; Navarro JA; Rivera P; Rosell-Valle C; Gutiérrez-Adán A; Sanjuan C; López-Gambero AJ; Tovar R; Suárez J; Pavón FJ; Baixeras E; Decara J; Rodríguez de Fonseca F
Br J Pharmacol; 2022 Oct; 179(19):4655-4672. PubMed ID: 35760415
[TBL] [Abstract][Full Text] [Related]
76. Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice.
Yao Y; Chang Y; Li S; Zhu J; Wu Y; Jiang X; Li L; Liu R; Ma R; Li G
Brain Res Bull; 2023 Aug; 200():110685. PubMed ID: 37330021
[TBL] [Abstract][Full Text] [Related]
77. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
Hanger DP; Anderton BH; Noble W
Trends Mol Med; 2009 Mar; 15(3):112-9. PubMed ID: 19246243
[TBL] [Abstract][Full Text] [Related]
78. Tau and tauopathies.
Robert M; Mathuranath PS
Neurol India; 2007; 55(1):11-6. PubMed ID: 17272893
[TBL] [Abstract][Full Text] [Related]
79. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
80. Shaggy functions downstream of dMyc and their concurrent downregulation confers additive rescue against tau toxicity in Drosophila.
Pragati ; Sarkar S
Biofactors; 2021 May; 47(3):461-477. PubMed ID: 33651466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
